Compare OneSpan Inc (OSPN) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Twist Bioscience Corp — how do they compare? OneSpan Inc trades at $16.12 (market cap $593.32M), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is far larger — about 14.2× OneSpan Inc's market cap, and OneSpan Inc pays a 3.23% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| OSPN | TWST | |
|---|---|---|
Market Cap | $593.32M | $8.42B |
Sector | Technology | Health |
52-Week High | $16.92 | $153.10 |
52-Week Low | $10.15 | $24.16 |
Enterprise Value | $562.40M | $8.35B |
Dividend Yield | 3.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $16.1, down 3.59% on the day, with technical indicators showing a neutral trend and key support at $16. The stock exhibits strong fundamentals, including a P/E of 9.1, robust profitability margins, and consistent earnings beats in recent quarters. Recent news highlights institutional interest, such as Deutsche Bank's new position, and the company's introduction of DigipassONE for authentication modernization.
The outlook for OSPN is positive, supported by solid financials and analyst consensus, but risks include competitive pressures and cash flow volatility. With a consensus price target of $17.00 and 66.67% buy ratings, the stock offers potential upside, though investors should monitor execution risks and market sentiment shifts.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
